AwardedSpainGoodsDynamic purchasing system
Bioloogiliste ravimite hankimine 2026
- Published
- Published 3 October 2024
Overview
Tervisekassa has awarded a contract for the procurement of biological medicines containing active substances bevacizumab, nab-paclitaxel, tocilizumab, trastuzumab, rituximab, and infliximab, valued at EUR 4,462,882.64. The contract was awarded on 14 July 2026 to four suppliers: Farmatar OÜ, MAGNUM MEDICAL OÜ, Roche Eesti Osaühing, and TAMRO EESTI OÜ, with participation from HVA hospitals.
Key details
- Country
- Spain
- Status
- Awarded
- Category
- Goods
- Procedure
- Selective
- Contract type
- Dynamic purchasing system
- Published
- 3 October 2024
Pharmaceutical products
Award outcome
- Awarded value
- €4,462,883
- Award date
- 14 July 2026
- Contract period
- 27 September 2024 → 12 September 2027
- Farmatar OÜ
- MAGNUM MEDICAL OÜ
- Roche Eesti Osaühing
- TAMRO EESTI OÜ
Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.
Notice history
Every published notice in this contracting process, newest first.
Contract Award Notice
17 July 2026
Contract Award Notice
12 November 2025
Contract Award Notice
15 July 2025
Contract Award Notice
10 July 2025
Contract Award Notice
16 December 2024
Contract Notice
3 October 2024
Contracting authority
Tervisekassa
Procuring entityTallinn, Spain
Authority website ↗
Get the full picture
AI analysis, bid scoring, and expert strategy for this tender
Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.
See which competitors are winning the contracts you're chasing.
15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.